228 related articles for article (PubMed ID: 17337182)
21. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
Eardley I
Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
[No Abstract] [Full Text] [Related]
22. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
[TBL] [Abstract][Full Text] [Related]
23. 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6.
Duan H; Zheng J; Lai Q; Liu Z; Tian G; Wang Z; Li J; Shen J
Bioorg Med Chem Lett; 2009 May; 19(10):2777-9. PubMed ID: 19375311
[TBL] [Abstract][Full Text] [Related]
24. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.
Gupta M; Kovar A; Meibohm B
J Clin Pharmacol; 2005 Sep; 45(9):987-1003. PubMed ID: 16100293
[TBL] [Abstract][Full Text] [Related]
25. Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.
Haning H; Niewöhner U; Schenke T; Lampe T; Hillisch A; Bischoff E
Bioorg Med Chem Lett; 2005 Sep; 15(17):3900-7. PubMed ID: 15993055
[TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase type 5 inhibithors in older males.
Frajese GV; Pozzi F
J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):112-5. PubMed ID: 16760638
[TBL] [Abstract][Full Text] [Related]
27. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 1: 5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.
Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Kirilovsky J; Hyafil F; Labaudinière R
J Med Chem; 2003 Oct; 46(21):4525-32. PubMed ID: 14521414
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
[TBL] [Abstract][Full Text] [Related]
29. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon?
Lincoln TM
Mol Pharmacol; 2004 Jul; 66(1):11-3. PubMed ID: 15213291
[No Abstract] [Full Text] [Related]
30. Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds.
Francis SH; Sekhar KR; Ke H; Corbin JD
Handb Exp Pharmacol; 2011; (200):93-133. PubMed ID: 20859794
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
Rosen RC; Shaw JW
Int J Impot Res; 2006; 18(6):570-1; author reply 572-3. PubMed ID: 17075585
[No Abstract] [Full Text] [Related]
32. New pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective PDE5 inhibitors.
Feixas J; Giovannoni MP; Vergelli C; Gavaldà A; Cesari N; Graziano A; Dal Piaz V
Bioorg Med Chem Lett; 2005 May; 15(9):2381-4. PubMed ID: 15837329
[TBL] [Abstract][Full Text] [Related]
33. Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction.
Yu G; Mason HJ; Wu X; Wang J; Chong S; Dorough G; Henwood A; Pongrac R; Seliger L; He B; Normandin D; Adam L; Krupinski J; Macor JE
J Med Chem; 2001 Mar; 44(7):1025-7. PubMed ID: 11297448
[No Abstract] [Full Text] [Related]
34. Transient global amnesia after intake of tadalafil, a PDE-5 inhibitor: a possible association?
Schiefer J; Sparing R
Int J Impot Res; 2005; 17(4):383-4. PubMed ID: 15674402
[TBL] [Abstract][Full Text] [Related]
35. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
Burnett AL
Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
[No Abstract] [Full Text] [Related]
36. Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.
Haning H; Niewöhner U; Schenke T; Es-Sayed M; Schmidt G; Lampe T; Bischoff E
Bioorg Med Chem Lett; 2002 Mar; 12(6):865-8. PubMed ID: 11958981
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and phosphodiesterase 5 inhibitory activity of novel pyrido[1,2-e]purin-4(3H)-one derivatives.
Xia G; Li J; Peng A; Lai S; Zhang S; Shen J; Liu Z; Chen X; Ji R
Bioorg Med Chem Lett; 2005 Jun; 15(11):2790-4. PubMed ID: 15878277
[TBL] [Abstract][Full Text] [Related]
38. Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema.
Bates MG; Thompson AA; Baillie JK
Curr Opin Investig Drugs; 2007 Mar; 8(3):226-31. PubMed ID: 17408118
[TBL] [Abstract][Full Text] [Related]
39. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Bella AJ; Brant WO; Lue TF; Brock GB
Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
[TBL] [Abstract][Full Text] [Related]
40. Rationale for androgens and erectile dysfunction in 2006.
Roumeguère T
Eur Urol; 2006 Nov; 50(5):898-900. PubMed ID: 16893603
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
